Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial
• Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II.
Autor*in: |
Irtan, Sabine [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2019 |
---|
Schlagwörter: |
---|
Umfang: |
7 |
---|
Übergeordnetes Werk: |
Enthalten in: Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells - Han, Xiaobing ELSEVIER, 2021, journal of the European Society for Therapeutic Radiology and Oncology, Amsterdam [u.a.] |
---|---|
Übergeordnetes Werk: |
volume:131 ; year:2019 ; pages:1-7 ; extent:7 |
Links: |
---|
DOI / URN: |
10.1016/j.radonc.2018.10.026 |
---|
Katalog-ID: |
ELV045821070 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | ELV045821070 | ||
003 | DE-627 | ||
005 | 20230624120408.0 | ||
007 | cr uuu---uuuuu | ||
008 | 191021s2019 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.radonc.2018.10.026 |2 doi | |
028 | 5 | 2 | |a GBV00000000000523.pica |
035 | |a (DE-627)ELV045821070 | ||
035 | |a (ELSEVIER)S0167-8140(18)33550-3 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 570 |a 540 |q VZ |
100 | 1 | |a Irtan, Sabine |e verfasserin |4 aut | |
245 | 1 | 0 | |a Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial |
264 | 1 | |c 2019 | |
300 | |a 7 | ||
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a nicht spezifiziert |b z |2 rdamedia | ||
338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
520 | |a • Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II. | ||
650 | 7 | |a Wilms tumour |2 Elsevier | |
650 | 7 | |a Stage III |2 Elsevier | |
650 | 7 | |a Radiotherapy |2 Elsevier | |
700 | 1 | |a Messahel, Boo |4 oth | |
700 | 1 | |a Moroz, Veronica |4 oth | |
700 | 1 | |a Taylor, Roger E. |4 oth | |
700 | 1 | |a Grundy, Richard |4 oth | |
700 | 1 | |a Kelsey, Anna |4 oth | |
700 | 1 | |a Vujanic, Gordan |4 oth | |
700 | 1 | |a Pritchard-Jones, Kathy |4 oth | |
773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Han, Xiaobing ELSEVIER |t Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |d 2021 |d journal of the European Society for Therapeutic Radiology and Oncology |g Amsterdam [u.a.] |w (DE-627)ELV00004122X |
773 | 1 | 8 | |g volume:131 |g year:2019 |g pages:1-7 |g extent:7 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.radonc.2018.10.026 |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SYSFLAG_U | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 131 |j 2019 |h 1-7 |g 7 |
author_variant |
s i si |
---|---|
matchkey_str |
irtansabinemessahelboomorozveronicataylo:2019----:ucmsfoaalsisaeiadnprbeimtmut |
hierarchy_sort_str |
2019 |
publishDate |
2019 |
allfields |
10.1016/j.radonc.2018.10.026 doi GBV00000000000523.pica (DE-627)ELV045821070 (ELSEVIER)S0167-8140(18)33550-3 DE-627 ger DE-627 rakwb eng 570 540 VZ Irtan, Sabine verfasserin aut Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II. Wilms tumour Elsevier Stage III Elsevier Radiotherapy Elsevier Messahel, Boo oth Moroz, Veronica oth Taylor, Roger E. oth Grundy, Richard oth Kelsey, Anna oth Vujanic, Gordan oth Pritchard-Jones, Kathy oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:131 year:2019 pages:1-7 extent:7 https://doi.org/10.1016/j.radonc.2018.10.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 131 2019 1-7 7 |
spelling |
10.1016/j.radonc.2018.10.026 doi GBV00000000000523.pica (DE-627)ELV045821070 (ELSEVIER)S0167-8140(18)33550-3 DE-627 ger DE-627 rakwb eng 570 540 VZ Irtan, Sabine verfasserin aut Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II. Wilms tumour Elsevier Stage III Elsevier Radiotherapy Elsevier Messahel, Boo oth Moroz, Veronica oth Taylor, Roger E. oth Grundy, Richard oth Kelsey, Anna oth Vujanic, Gordan oth Pritchard-Jones, Kathy oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:131 year:2019 pages:1-7 extent:7 https://doi.org/10.1016/j.radonc.2018.10.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 131 2019 1-7 7 |
allfields_unstemmed |
10.1016/j.radonc.2018.10.026 doi GBV00000000000523.pica (DE-627)ELV045821070 (ELSEVIER)S0167-8140(18)33550-3 DE-627 ger DE-627 rakwb eng 570 540 VZ Irtan, Sabine verfasserin aut Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II. Wilms tumour Elsevier Stage III Elsevier Radiotherapy Elsevier Messahel, Boo oth Moroz, Veronica oth Taylor, Roger E. oth Grundy, Richard oth Kelsey, Anna oth Vujanic, Gordan oth Pritchard-Jones, Kathy oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:131 year:2019 pages:1-7 extent:7 https://doi.org/10.1016/j.radonc.2018.10.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 131 2019 1-7 7 |
allfieldsGer |
10.1016/j.radonc.2018.10.026 doi GBV00000000000523.pica (DE-627)ELV045821070 (ELSEVIER)S0167-8140(18)33550-3 DE-627 ger DE-627 rakwb eng 570 540 VZ Irtan, Sabine verfasserin aut Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II. Wilms tumour Elsevier Stage III Elsevier Radiotherapy Elsevier Messahel, Boo oth Moroz, Veronica oth Taylor, Roger E. oth Grundy, Richard oth Kelsey, Anna oth Vujanic, Gordan oth Pritchard-Jones, Kathy oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:131 year:2019 pages:1-7 extent:7 https://doi.org/10.1016/j.radonc.2018.10.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 131 2019 1-7 7 |
allfieldsSound |
10.1016/j.radonc.2018.10.026 doi GBV00000000000523.pica (DE-627)ELV045821070 (ELSEVIER)S0167-8140(18)33550-3 DE-627 ger DE-627 rakwb eng 570 540 VZ Irtan, Sabine verfasserin aut Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II. Wilms tumour Elsevier Stage III Elsevier Radiotherapy Elsevier Messahel, Boo oth Moroz, Veronica oth Taylor, Roger E. oth Grundy, Richard oth Kelsey, Anna oth Vujanic, Gordan oth Pritchard-Jones, Kathy oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:131 year:2019 pages:1-7 extent:7 https://doi.org/10.1016/j.radonc.2018.10.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 131 2019 1-7 7 |
language |
English |
source |
Enthalten in Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells Amsterdam [u.a.] volume:131 year:2019 pages:1-7 extent:7 |
sourceStr |
Enthalten in Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells Amsterdam [u.a.] volume:131 year:2019 pages:1-7 extent:7 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Wilms tumour Stage III Radiotherapy |
dewey-raw |
570 |
isfreeaccess_bool |
false |
container_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
authorswithroles_txt_mv |
Irtan, Sabine @@aut@@ Messahel, Boo @@oth@@ Moroz, Veronica @@oth@@ Taylor, Roger E. @@oth@@ Grundy, Richard @@oth@@ Kelsey, Anna @@oth@@ Vujanic, Gordan @@oth@@ Pritchard-Jones, Kathy @@oth@@ |
publishDateDaySort_date |
2019-01-01T00:00:00Z |
hierarchy_top_id |
ELV00004122X |
dewey-sort |
3570 |
id |
ELV045821070 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV045821070</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624120408.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.radonc.2018.10.026</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000523.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV045821070</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-8140(18)33550-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Irtan, Sabine</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Wilms tumour</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Stage III</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Radiotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Messahel, Boo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moroz, Veronica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taylor, Roger E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grundy, Richard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kelsey, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vujanic, Gordan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pritchard-Jones, Kathy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Han, Xiaobing ELSEVIER</subfield><subfield code="t">Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells</subfield><subfield code="d">2021</subfield><subfield code="d">journal of the European Society for Therapeutic Radiology and Oncology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00004122X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:131</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:1-7</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.radonc.2018.10.026</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">131</subfield><subfield code="j">2019</subfield><subfield code="h">1-7</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
author |
Irtan, Sabine |
spellingShingle |
Irtan, Sabine ddc 570 Elsevier Wilms tumour Elsevier Stage III Elsevier Radiotherapy Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial |
authorStr |
Irtan, Sabine |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV00004122X |
format |
electronic Article |
dewey-ones |
570 - Life sciences; biology 540 - Chemistry & allied sciences |
delete_txt_mv |
keep |
author_role |
aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
570 540 VZ Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial Wilms tumour Elsevier Stage III Elsevier Radiotherapy Elsevier |
topic |
ddc 570 Elsevier Wilms tumour Elsevier Stage III Elsevier Radiotherapy |
topic_unstemmed |
ddc 570 Elsevier Wilms tumour Elsevier Stage III Elsevier Radiotherapy |
topic_browse |
ddc 570 Elsevier Wilms tumour Elsevier Stage III Elsevier Radiotherapy |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
zu |
author2_variant |
b m bm v m vm r e t re ret r g rg a k ak g v gv k p j kpj |
hierarchy_parent_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
hierarchy_parent_id |
ELV00004122X |
dewey-tens |
570 - Life sciences; biology 540 - Chemistry |
hierarchy_top_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)ELV00004122X |
title |
Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial |
ctrlnum |
(DE-627)ELV045821070 (ELSEVIER)S0167-8140(18)33550-3 |
title_full |
Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial |
author_sort |
Irtan, Sabine |
journal |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
journalStr |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
500 - Science |
recordtype |
marc |
publishDateSort |
2019 |
contenttype_str_mv |
zzz |
container_start_page |
1 |
author_browse |
Irtan, Sabine |
container_volume |
131 |
physical |
7 |
class |
570 540 VZ |
format_se |
Elektronische Aufsätze |
author-letter |
Irtan, Sabine |
doi_str_mv |
10.1016/j.radonc.2018.10.026 |
dewey-full |
570 540 |
title_sort |
outcomes of non-anaplastic stage iii and ‘inoperable’ wilms tumour treated in the ukw3 trial |
title_auth |
Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial |
abstract |
• Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II. |
abstractGer |
• Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II. |
abstract_unstemmed |
• Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II. |
collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
title_short |
Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial |
url |
https://doi.org/10.1016/j.radonc.2018.10.026 |
remote_bool |
true |
author2 |
Messahel, Boo Moroz, Veronica Taylor, Roger E. Grundy, Richard Kelsey, Anna Vujanic, Gordan Pritchard-Jones, Kathy |
author2Str |
Messahel, Boo Moroz, Veronica Taylor, Roger E. Grundy, Richard Kelsey, Anna Vujanic, Gordan Pritchard-Jones, Kathy |
ppnlink |
ELV00004122X |
mediatype_str_mv |
z |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth oth oth oth oth oth oth |
doi_str |
10.1016/j.radonc.2018.10.026 |
up_date |
2024-07-06T18:34:43.406Z |
_version_ |
1803855733360427008 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV045821070</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624120408.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.radonc.2018.10.026</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000523.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV045821070</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-8140(18)33550-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Irtan, Sabine</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Wilms tumour</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Stage III</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Radiotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Messahel, Boo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moroz, Veronica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taylor, Roger E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grundy, Richard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kelsey, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vujanic, Gordan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pritchard-Jones, Kathy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Han, Xiaobing ELSEVIER</subfield><subfield code="t">Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells</subfield><subfield code="d">2021</subfield><subfield code="d">journal of the European Society for Therapeutic Radiology and Oncology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00004122X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:131</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:1-7</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.radonc.2018.10.026</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">131</subfield><subfield code="j">2019</subfield><subfield code="h">1-7</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
score |
7.4003096 |